Cargando…

Peptide-Based Vaccines and Therapeutics for COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been prevalent in the humans since 2019 and has given rise to a pandemic situation. With the discovery and ongoing use of drugs and vaccines against SARS-CoV-2, there is still no surety of its complete suppression of this disease or if...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagwe, Pritam V., Bagwe, Priyal V., Ponugoti, Sai Srinivas, Joshi, Shreerang V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017722/
https://www.ncbi.nlm.nih.gov/pubmed/35463185
http://dx.doi.org/10.1007/s10989-022-10397-y
_version_ 1784688838216515584
author Bagwe, Pritam V.
Bagwe, Priyal V.
Ponugoti, Sai Srinivas
Joshi, Shreerang V.
author_facet Bagwe, Pritam V.
Bagwe, Priyal V.
Ponugoti, Sai Srinivas
Joshi, Shreerang V.
author_sort Bagwe, Pritam V.
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been prevalent in the humans since 2019 and has given rise to a pandemic situation. With the discovery and ongoing use of drugs and vaccines against SARS-CoV-2, there is still no surety of its complete suppression of this disease or if there is a need for additional booster doses. There is an urgent need for alternative treatment strategies against COVID-19. Peptides and peptidomimetics have several advantages as therapeutic agents because of their target selectivity, better interactions, and lower toxicity. Minor structural alterations to peptides can help prevent their fast metabolism and provide long-action. This comprehensive review provides an overview of different peptide-based vaccines and therapeutics against SARS-CoV-2. It discusses the design and mechanism of action of the peptide-based vaccines, peptide immunomodulators, anti-inflammatory agents, and peptides as entry inhibitors of SARS-CoV-2. Moreover, the mechanism of action, sequences and current clinical trial studies are also summarized. The review also discusses the future aspects of peptide-based vaccines and therapeutics for COVID-19. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9017722
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-90177222022-04-20 Peptide-Based Vaccines and Therapeutics for COVID-19 Bagwe, Pritam V. Bagwe, Priyal V. Ponugoti, Sai Srinivas Joshi, Shreerang V. Int J Pept Res Ther Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been prevalent in the humans since 2019 and has given rise to a pandemic situation. With the discovery and ongoing use of drugs and vaccines against SARS-CoV-2, there is still no surety of its complete suppression of this disease or if there is a need for additional booster doses. There is an urgent need for alternative treatment strategies against COVID-19. Peptides and peptidomimetics have several advantages as therapeutic agents because of their target selectivity, better interactions, and lower toxicity. Minor structural alterations to peptides can help prevent their fast metabolism and provide long-action. This comprehensive review provides an overview of different peptide-based vaccines and therapeutics against SARS-CoV-2. It discusses the design and mechanism of action of the peptide-based vaccines, peptide immunomodulators, anti-inflammatory agents, and peptides as entry inhibitors of SARS-CoV-2. Moreover, the mechanism of action, sequences and current clinical trial studies are also summarized. The review also discusses the future aspects of peptide-based vaccines and therapeutics for COVID-19. GRAPHICAL ABSTRACT: [Image: see text] Springer Netherlands 2022-04-19 2022 /pmc/articles/PMC9017722/ /pubmed/35463185 http://dx.doi.org/10.1007/s10989-022-10397-y Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Bagwe, Pritam V.
Bagwe, Priyal V.
Ponugoti, Sai Srinivas
Joshi, Shreerang V.
Peptide-Based Vaccines and Therapeutics for COVID-19
title Peptide-Based Vaccines and Therapeutics for COVID-19
title_full Peptide-Based Vaccines and Therapeutics for COVID-19
title_fullStr Peptide-Based Vaccines and Therapeutics for COVID-19
title_full_unstemmed Peptide-Based Vaccines and Therapeutics for COVID-19
title_short Peptide-Based Vaccines and Therapeutics for COVID-19
title_sort peptide-based vaccines and therapeutics for covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017722/
https://www.ncbi.nlm.nih.gov/pubmed/35463185
http://dx.doi.org/10.1007/s10989-022-10397-y
work_keys_str_mv AT bagwepritamv peptidebasedvaccinesandtherapeuticsforcovid19
AT bagwepriyalv peptidebasedvaccinesandtherapeuticsforcovid19
AT ponugotisaisrinivas peptidebasedvaccinesandtherapeuticsforcovid19
AT joshishreerangv peptidebasedvaccinesandtherapeuticsforcovid19